Member Info for lofas

Covid trial outcome is unlikely to be positive. Shame it is one of the concurrent attempts on goal.

It’s insane to think that SC has their T cell covid response and on paper SC DNA covid vaccine is Miles ahead of the competition. Next deal is about to become public? What a nice xmas present it will be.

Where.when can we expect SC to update regarding the ongoing SA trial ?

Let’s wish…

Good summary of what is happening. Vacuum between RNSs and weakening of SP. Unfortunately regardless of the enormous scientific advances and that will continue up to a TO or commercialisation of platforms/products. Too big tasks on the shoulders of 40 employees.

Do we know how many active patients currently participating across all open centres ? Full participation is set to 125?

Understood, thanks!

It is puzzling why SC and the ongoing trail are not mentioned. Instead the article is with references to a study base on 16 patients with tailor made treatment. Wishing them all the best and hope it works.

Always thought that success can be diluted over time. It’s great that you have not lost the believe in SC & LD.
Modi1 feedback so far and cash investment in new tech for modi2 are both indications to modi1 trail success outcome. Very interesting period.GLA

The revolutionary idea of ??the Israeli start-up company

Imagene, an Israeli start-up company, came up with a revolutionary idea: each unique mutation will have its own effect on the cancer cell. Therefore cancer cells carrying different mutations will look different. The problem - the human eye is not able to find the differences, they are too small. To overcome the problem, the company uses the digital pathology capability of the Institute of Pathology in Ichilov. Thanks to this ability, the appearance of the tumor under the microscope can be turned into extremely high resolution images. The company has developed a special algorithm, capable of identifying the unique appearance of cells that have different mutations. In this way, the presence of a mutation can be predicted within minutes, immediately after looking at the tumor under a microscope, without the need for a complex genetic test

Where you see discrepancy ? My previous post was in my view positive, not intended to raise concern or doubt in future prospects,

RR, that’s long wait…any shortcut scenarios ?

Relatively toxic instead of highly toxic….

If not mistaken it’s a highly toxic treatment. If modi-1 efficacy is proven with high degree of confidence when can we expect to see it on the shelf ?

WF, a very sensible conclusion. Unlike one would choose the word combo unless they sense , that as far as effectiveness , they are very close to a milestone .announcement

Berms, Thanks for the feedback.

RP, got it thanks. Can we assume that from IP perspective each firm will keep hold on the IP they already have in the draw?

Hyms, thanks. So what will be the significance of todays RNS from SC perspective. Assuming the aim is to expedite to possible commercialisation l, trails first of modi-2.

As far as IP…is it not 2 separate discussion items, Platform and formulation ?

Never invest in something you don’t understand.